JMD ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jeuken, J.
Right arrow Articles by Wesseling, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeuken, J.
Right arrow Articles by Wesseling, P.
JMD 2006, Vol. 8, No. 4
Copyright © 2006 American Society for Investigative Pathology & Association for Molecular Pathology

Technical Advance

Multiplex Ligation-Dependent Probe Amplification

A Diagnostic Tool for Simultaneous Identification of Different Genetic Markers in Glial Tumors

Judith Jeuken*, Sandra Cornelissen*, Sandra Boots-Sprenger*{dagger}, Sabine Gijsen* and Pieter Wesseling*

From the Departments of Pathology * and Neurology, {dagger} Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Abstract

Genetic aberrations in tumors are predictive for chemosensitivity and survival. A test is needed that allows simultaneous detection of multiple changes and that is widely applicable in a routine diagnostic setting. Multiplex ligation-dependent probe amplification (MLPA) allows detection of DNA copy number changes of up to 45 loci in one relatively simple, semiquantitative polymerase chain reaction-based assay. To assess the applicability of MLPA, we performed MLPA analysis to detect relevant genetic markers in a spectrum of 88 gliomas. The vast majority of these tumors (n = 79) were previously characterized by comparative genomic hybridization. With MLPA kit P088 (78 cases), complete and partial loss of 1p and 19q were reliably identified, even in samples containing only 50% tumor DNA. Distinct 1p deletions exist with different clinically prognostic consequences, and in contrast to the commonly used diagnostic strategies (loss of heterozygosity or fluorescent in situ hybridization 1p36), P088 allows detection of such distinct 1p losses. Combining P088 with P105 will further increase the accurate prediction of clinical behavior because this kit identified markers (EGFR, PTEN, and CDKN2A) of high-grade malignancy in 41 cases analyzed. We conclude that MLPA is a reliable diagnostic tool for simultaneous identification of different region-specific genetic aberrations of tumors.




This article has been cited by other articles:


Home page
 Neuro OncolHome page
N. Holtkamp, E. Malzer, J. Zietsch, A. F. Okuducu, J. Mucha, C. Mawrin, V.-F. Mautner, H.-U. Schildhaus, and A. von Deimling
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy
Neuro-oncol, January 1, 2008; 10(6): 946 - 957.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
The German Glioma Network, M. Weller, H. Berger, C. Hartmann, J. Schramm, M. Westphal, M. Simon, R. Goldbrunner, D. Krex, J. P. Steinbach, et al.
Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker?
Clin. Cancer Res., December 1, 2007; 13(23): 6933 - 6937.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
D. Krex, B. Klink, C. Hartmann, A. von Deimling, T. Pietsch, M. Simon, M. Sabel, J. P. Steinbach, O. Heese, G. Reifenberger, et al.
Long-term survival with glioblastoma multiforme
Brain, October 1, 2007; 130(10): 2596 - 2606.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society for Investigative Pathology and the Association for Molecular Pathology.